Patents Examined by Daniel R Carcanague
  • Patent number: 11629128
    Abstract: Disclosed herein are embodiments of a compound that can be used as a supramolecular sensor for determining the presence of analytes (e.g., illicit drugs), and for identifying and/or quantifying the analytes. Also disclosed herein is a parallel synthesis method for making compound embodiments, as well as method embodiments for using the compound embodiments. Array embodiments comprising one or more compound embodiments disclosed herein also are described.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: April 18, 2023
    Assignee: UVic Industry Partnerships Inc.
    Inventors: Meagan Beatty, Fraser Hof, Allison Selinger
  • Patent number: 11622956
    Abstract: Described is a cannabinoid-terpenoid solution (CTS) and method of treating a disease state or condition in animals other than humans via cannabinoid-terpenoid therapy. The CTS includes a unique combination of cannabinoids, terpenoids (terpenes), and a lipophilic carrier to allow safely and effectively treat the animal.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: April 11, 2023
    Assignee: RCR Biopharma
    Inventor: Irena Raskin
  • Patent number: 11613535
    Abstract: There is disclosed a compound, a pharmaceutical composition and a method of cancer treatment with an improved Myc inhibitor compound. More specifically, there is disclosed an improved compound having with improved solubility, improved binding characteristics and better efficacy and therapeutic activity inhibiting c-MYC wherein the improved compound comprises a tri-substituted pyridine having a thiazoyl moiety at position R1 versus an earlier disclosed genus of tri-substituted pyridine structures.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: March 28, 2023
    Assignee: The Scripps Research Institute
    Inventor: Kim D. Janda
  • Patent number: 11608325
    Abstract: A polycrystalline form of a dehydrophenylahistin-like compound, and a manufacturing and purification method and application thereof. A (3Z,6Z)-3-benzylidene-6-[(5-tert-butyl-1H-imidazol-4-yl)deuteromethylene]piperazine-2,5-dione monohydrate crystal and a (3Z,6Z-3-benzylidene-6-[(5-tert-butyl-1H-imidazol-4-yl)methylene]piperazine-2,5-dione monohydrate crystal are more competitive crystalline forms with stable quality. The manufacturing and purification method is simple and easy to operate, and can effectively control the generation of a trans-isomer contaminant to obtain a high purity product. The polycrystalline form of the dehydrophenylahistin-like compound has a certain value in an application for manufacturing an antitumor pharmaceutical product.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: March 21, 2023
    Assignee: SHENZHEN HUAHONG MARINE BIOMEDICINE CO., LTD.
    Inventors: Wenbao Li, Shixiao Wang, Zhongpeng Ding, Yingwei Hou, Huashi Guan
  • Patent number: 11602546
    Abstract: A composition inhibiting MEIS proteins. The MEIS proteins are effective in proliferation of hematopoietic stem cells. A formulation capable of easily passing through the cell membrane and perform its activity in the cell, and can inhibit MEIS activity in a dose dependent manner. The combination includes isolated cells, medium, growth factors and MEISi inhibitor. The isolated cells are isolated from mouse bone marrow, human bone marrow and human umbilical cord blood. The medium has a pH value of 7.2 and contains bovine serum albumin, recombinant insulin, transferrin, 2-mercaptoethanol and IMDM medium. The growth factors are hematopoietic stem cell factor SCF, fetus liver tyrosine kinase-3 ligand Flt3L, and thrombopoietin. A chemical formula of the MEISi-1 is 4-[2-(benzylamino)-2-oxoethoxy]-N-(2,3-dimethylphenyl) benzamide. A chemical formula of MEISi-2 is 4-hydroxy-N?-[(Z)-(2-oxonaphthalen-1-ylidene)methyl] benzohydrazide.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: March 14, 2023
    Assignee: YEDITEPE UNIVERSITESI
    Inventors: Fatih Kocabas, Raife Dilek Turan
  • Patent number: 11603376
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: March 14, 2023
    Assignee: The Regents of the University of California
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • Patent number: 11582970
    Abstract: Provided are 2-aminoimidazole-phenyl derivative compounds of Formula (I): which compounds are useful in methods of controlling microbial growth, such as by enhancing the effects of an antibiotic administered in combination with the compound. Compositions including these compounds, devices including these compounds, and methods of using the same are also provided.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: February 21, 2023
    Assignee: North Carolina State University
    Inventors: Christian Melander, David Kendall Jung, Samuel Onofre Reyes
  • Patent number: 11584744
    Abstract: The present disclosure is generally directed to compositions useful in the inhibition of MetRS and methods for treating diseases that are ameliorated by the inhibition of MetRS.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: February 21, 2023
    Assignee: University of Washington
    Inventors: Erkang Fan, Zhongsheng Zhang, Wenlin Huang, Frederick S. Buckner
  • Patent number: 11584742
    Abstract: Compounds represented by the structural formula (1) R1, R2, R3, R4, R5, R6 are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: February 21, 2023
    Assignee: MASARYKOVA UNIVERZITA
    Inventors: Kamil Paruch, Benoit Carbain, Stepan Havel, Jiri Damborsky, Jan Brezovsky, Lukas Daniel, Alexandra Sisakova, Fedor Nikulenkov, Lumir Krejci
  • Patent number: 11576878
    Abstract: Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: February 14, 2023
    Assignee: LABOMED PHARMACEUTICAL COMPANY S.A.
    Inventors: Georgios Liolios, Ioannis Psarrakis
  • Patent number: 11578057
    Abstract: A polycrystalline form of a dehydrophenylahistin-like compound, and a manufacturing and purification method and application thereof. A (3Z,6Z)-3-benzylidene-6-[(5-tert-butyl-1H-imidazol-4-yl)deuteromethylene]piperazine-2,5-dione monohydrate crystal and a (3Z,6Z)-3-benzylidene-6-[(5-tert-butyl-1H-imidazol-4-yl)methylene]piperazine-2,5-dione monohydrate crystal are more competitive crystalline forms with stable quality. The manufacturing and purification method is simple and easy to operate, and can effectively control the generation of a trans-isomer contaminant to obtain a high purity product. The polycrystalline form of the dehydrophenylahistin-like compound has a certain value in an application for manufacturing an antitumor pharmaceutical product.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: February 14, 2023
    Assignee: Shenzhen Huahong Marine Biomedicine Co., Ltd.
    Inventors: Wenbao Li, Shixiao Wang, Zhongpeng Ding, Yingwei Hou, Huashi Guan
  • Patent number: 11566014
    Abstract: Cationic radial catenane comprising a central cationic ring and two or more radial cationic rings mechanically interlocked central cationic ring and methods for making the same are disclosed herein.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 31, 2023
    Assignees: Northwestern University, King Abdulaziz City for Science and Technology (KACST)
    Inventors: Minh T. Nguyen, James Fraser Stoddart
  • Patent number: 11560366
    Abstract: Disclosed herein are compounds which inhibit the kinase activity of dual leucine zipper (DLK) kinase (MAP3K12), pharmaceutical compositions, and methods of treatment of DLK-mediated diseases, such as neurological diseases that result from traumatic injury to central nervous system and peripheral nervous system neurons (e.g. stroke, traumatic brain injury, spinal cord injury), or that result from a chronic neurodegenerative condition (e.g. Alzheimer's disease, frontotemporal dementia, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, spinocerebellar ataxia, progressive supranuclear palsy, Lewy body disease, Kennedy's disease, and other related conditions), from neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and related conditions) and from cognitive disorders caused by pharmacological intervention (e.g. chemotherapy induced cognitive disorder, also known as chemobrain).
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: January 24, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael J. Soth, Kang Le, Philip Jones, Jason Cross
  • Patent number: 11555019
    Abstract: The present invention relates to peptide conjugates of microtubule-targeting agents such as maytansinoid derivatives which are useful for the treatment of diseases such as cancer.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: January 17, 2023
    Assignee: Cybrexa 3, Inc.
    Inventors: Daniel Richard Marshall, Johanna Marie Csengery, Robert John Maguire, Robert A. Volkmann
  • Patent number: 11554127
    Abstract: Provided herein is a combination product comprising a Bcl-2 inhibitor, an anti-CD20 antibody and/or bendamustine or a combination product comprising a Bcl-2 inhibitor and CHOP, the combination product provides a use of the combination product for prevention and/or treatment of a disease (e.g., cancer, rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis).
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: January 17, 2023
    Assignee: ASCENTAGE PHARMA (SUZHOU) CO., LTD.
    Inventors: Dajun Yang, Yifan Zhai, Guangfeng Wang
  • Patent number: 11554124
    Abstract: The purpose of the invention is to provide a novel hematopoiesis-promoting agent and a medicament comprising the hematopoiesis-promoting agent as an active ingredient for preventing or treating anemia, in particular refractory anemia. The present invention provides a hematopoiesis-promoting agent comprising an S-adenosylmethionine synthase inhibitor.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: January 17, 2023
    Assignee: TOHOKU UNIVERSITY
    Inventors: Kazuhiko Igarashi, Hiroki Kato, Yusho Ishii, Chi Long Nguyen, Hideo Harigae
  • Patent number: 11548867
    Abstract: Provided herein are compounds, compositions and methods of using the compounds and compositions for the treatment of diseases modulated, as least in part, by AhR. The compounds are represented by formulae Formula (I), (II), (III), (iv): wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: January 10, 2023
    Assignee: IDEA YA BIOSCIENCES, INC.
    Inventors: Muzaffar Alam, Hilary Plake Beck, Michael Patrick Dillon, Marcos Gonzalez-Lopez, Alice Chen Rico, James Clifford Sutton, Jr.
  • Patent number: 11548865
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: January 10, 2023
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • Patent number: 11542245
    Abstract: The present invention relates to a process for preparing 4-{[(2S)-2-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2H)-yl}butanoyl]amino}-2-fluorobenzamide (I) or 4-({(2S)-2-[4-{5-chloro-2-[4-(trifluoromethyl)-1H-1,2,3-triazol-1-yl]phenyl}-5-methoxy-2-oxopyridin-1(2H)-yl]butanoyl}amino)-2-fluorobenzamide (II) from 2,5-dimethoxypyridine (III), 1-(2-bromo-4-chlorophenyl)-4-chloro-1H-1,2,3-triazole (X-Cl) or 1-(2-bromo-4-chlorophenyl)-4-(trifluoromethyl)-1H-1,2,3-triazole (X-CF3), 4-amino-2-fluorbenzamide (XIII) and (2R)-2-aminobutanoic acid (XVII).
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: January 3, 2023
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Julian Egger, Daniel Goetz, Michal Sowa
  • Patent number: 11542457
    Abstract: Heterocycles having odoriferous ketone or odoriferous aldehyde groups may be suitable in compositions comprising washing agents, cleaning agents, cosmetic agents, air care agents, insect repellents, or combinations thereof where the heterocycles release the ketones and aldehydes during hydrolysis.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: January 3, 2023
    Assignee: Henkel AG & Co. KGaA
    Inventors: Sascha Wilhelm Schaefer, Benjamin Berntsson